Physician profile
Daniel Eric Levin
NPI 1740332956
$3,336.85
in general payments reported to CMS, 2019-2025
31 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $131 · 2021: $279 · 2022: $330 · 2023: $638 · 2024: $663 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.70 | 2022-2025 | Caplyta |
| Abbvie INC. | $437.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $244.06 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $241.65 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $237.60 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $219.70 | 2021-2024 | Trintellix |
| Lundbeck LLC | $169.39 | 2019-2024 | Rexulti |
| Alkermes, INC. | $153.70 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $128.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.00 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $104.21 | 2021-2022 | |
| Corium, LLC | $103.59 | 2022-2023 | Azstarys |
| Tris Pharma INC | $80.53 | 2022-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $69.13 | 2023-2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $61.53 | 2024 | Uzedy, Austedo Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $57.69 | 2024-2025 | Wegovy |
| Noven Therapeutics, LLC | $53.47 | 2023 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $43.75 | 2019 | |
| Uswm, LLC | $42.50 | 2022 | |
| Shire North American Group INC | $41.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $39.00 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $38.06 | 2023 | Xywav |
| Owp Pharmaceuticals, INC. | $34.89 | 2019 | |
| Livanova USA, INC. | $25.31 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Azurity Pharmaceuticals, INC. | $22.70 | 2023 | Horizant |
| Harmony Biosciences LLC | $22.47 | 2020 | |
| Almatica Pharma LLC | $22.16 | 2024 | Loreev Xr |
| Eisai INC. | $21.70 | 2021 | |
| Acadia Pharmaceuticals INC | $18.76 | 2019 | |
| Axsome Therapeutics, INC. | $18.21 | 2023 | Auvelity |
| Vertical Pharmaceuticals, LLC | $17.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.